Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01450826 · ClinicalTrials.gov registry record · Phase 2
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
A Phase 2 study, sponsored by Katy Peters.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT01450826 is a Phase 2 study that has completed, run by Katy Peters. The registered enrollment target is 136 participants.
The verdict
NCT01450826, a Phase 2 study, has completed, sponsored by Katy Peters.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
Patients diagnosed with malignant glioma who are receiving temozolomide will be accrued in this open label, phase 2, randomized single institution trial of aprepitant in combination with ondansetron versus ondansetron alone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Sixty-eight (68) patients will be randomized to each arm of the study.
Interventions
- DRUG ondansetron
- DRUG aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2014-06-24 |
| Est. Completion | 2017-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01450826
The ClinicalTrials.gov registry entry for NCT01450826 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Katy Peters, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ondansetron is the first listed.
NCT01450826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01450826 about?
NCT01450826 is a clinical study titled "Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide". Patients diagnosed with malignant glioma who are receiving temozolomide will be accrued in this open label, phase 2, randomized single institution trial of aprepitant in combination with ondansetron versus ondansetron alone for the prevention of acute and delayed chemotherapy-induced nausea and vomi...
What is the current status of trial NCT01450826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2014-06-24. Estimated completion is 2017-04-21.
What interventions are being tested in trial NCT01450826?
The interventions under investigation include: ondansetron (DRUG), aprepitant (DRUG).
Who is sponsoring clinical trial NCT01450826?
This trial is sponsored by Katy Peters, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.